Show simple item record

Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice

dc.contributor.authorSpiegel, Brennan M. R.en_US
dc.contributor.authorBolus, R.en_US
dc.contributor.authorHarris, L. A.en_US
dc.contributor.authorLucak, S.en_US
dc.contributor.authorChey, William D.en_US
dc.contributor.authorSayuk, G.en_US
dc.contributor.authorEsrailian, E.en_US
dc.contributor.authorLembo, Anthonyen_US
dc.contributor.authorKarsan, H.en_US
dc.contributor.authorTillisch, K.en_US
dc.contributor.authorTalley, J.en_US
dc.contributor.authorChang, L.en_US
dc.date.accessioned2011-01-31T17:56:48Z
dc.date.available2012-01-03T20:18:46Zen_US
dc.date.issued2010-11en_US
dc.identifier.citationSpiegel, B. M. R.; Bolus, R.; Harris, L. A.; Lucak, S.; Chey, W. D.; Sayuk, G.; Esrailian, E.; Lembo, A.; Karsan, H.; Tillisch, K.; Talley, J.; Chang, L.; (2010). "Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice." Alimentary Pharmacology & Therapeutics 32(9): 1192-1202. <http://hdl.handle.net/2027.42/79350>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/79350
dc.description.abstractAliment Pharmacol Ther 2010; 32: 1192–1202Although irritable bowel syndrome (IBS) is a multisymptom disorder, abdominal pain drives illness severity more than other symptoms. Despite consensus that IBS trials should measure pain to define study entry and determine efficacy, the optimal method of measuring pain remains uncertain.To determine whether combining information from multiple pain dimensions may capture the IBS illness experience more effectively than the approach of measuring ‘pain predominance’ or pain intensity alone.Irritable bowel syndrome patients rated dimensions of pain, including intensity, frequency, constancy, predominance, predictability, duration, speed of onset and relationship to bowel movements. We evaluated the impact of each dimension on illness severity using multivariable regression techniques.Among the pain dimensions, intensity, frequency, constancy and predictability were strongly and independently associated with illness severity; the other dimensions had weaker associations. The clinical definition of ‘pain predominance’, in which patients define pain as their most bothersome symptom, was insufficient to categorize patients by illness severity.Irritable bowel disease pain is multifaceted; some pain dimensions drive illness more than others. IBS trials should measure various pain dimensions, including intensity, constancy, frequency and predictability; this may improve upon the customary use of measuring pain as a unidimensional symptom in IBS.en_US
dc.format.extent315898 bytes
dc.format.extent3106 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.titleCharacterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practiceen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Health System, Ann Arbor, MI.en_US
dc.contributor.affiliationotherDepartment of Gastroenterology, VA Greater Los Angeles Healthcare System, Los Angeles, CA.en_US
dc.contributor.affiliationotherDavid Geffen School of Medicine at UCLA, Los Angeles, CA.en_US
dc.contributor.affiliationotherUCLA Center for Neurobiology of Stress, Los Angeles, CA.en_US
dc.contributor.affiliationotherUCLA/VA Center for Outcomes Research and Education (CORE), Los Angeles, CA.en_US
dc.contributor.affiliationotherDivision of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale.en_US
dc.contributor.affiliationotherDepartment of Gastroenterology, Columbia University, New York, NY.en_US
dc.contributor.affiliationotherDepartment of Gastroenterology, Washington University, St. Louis, Missouri.en_US
dc.contributor.affiliationotherDivision of Gastroenterology, Harvard Beth Israel Deaconess Medical Center, Boston, MA.en_US
dc.contributor.affiliationotherAtlanta Gastroenterology Associates, Atlanta, Georgia.en_US
dc.identifier.pmid20807217en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/79350/1/j.1365-2036.2010.04443.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2010.04443.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.